Actuate Therapeutics, Inc. - Common stock (ACTU)
ACTU moved a median of -1.43% 30 minutes after news, and -2.76% by the close. How ACTU actually reacts to news — the realized, point-in-time move the market made, measured across 170 labeled events over the last three years with zero look-ahead.
ACTU’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 34% | 146 |
| 30-min | -1.43% | 27% | 155 |
| 60-min | -2.27% | 31% | 158 |
| to close | -2.76% | 31% | 162 |
| Middle 50% of ACTU reactions | -3.47% to +0.31% |
|---|---|
| Median reaction (30-min) | -1.43% |
| Measured reactions | 170 |
Half of all Actuate Therapeutics, Inc. - Common stock news events land between -3.47% and +0.31% at 30 minutes.
Reaction stats as of 2026-08-31. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How ACTU reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Coverage initiations | 11 | -0.12% | 27% | -1.07% |
| Rating reiterations | 19 | +0.37% | 63% | +1.60% |
Last 3 years, pulled 2026-08-31. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 4 further classes were observed with fewer than 10 measured events and are not published. See how ACTU ranks against every other measured name →
That’s how ACTU usually reacts — get an email when it moves on news →Email me when ACTU moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to ACTU's baseline. Nothing else.
Recent ACTU events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 10-Q ACTUATE THERAPEUTICS, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | -2.94% | |
| Form 8-K ACTUATE THERAPEUTICS, For: Jul 15 | SEC filing · Form 8-K | SEC EDGAR | -0.66% | -8.50% | |
| Actuate Therapeutics’ Elraglusib Selected for Evaluation in BEACON2 Trial for High-Risk Pediatric Neuroblastoma | Press release | GlobeNewswire | +0.00% | +4.14% | |
| Actuate Therapeutics Announces ASCO Poster Presentations Demonstrating Compelling Clinical and Biomarker Data for Elraglusib in First-Line Metastatic Pancreatic Cancer | Press release | GlobeNewswire | +1.38% | -8.72% | |
| Form 8-K ACTUATE THERAPEUTICS, For: May 21 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -9.09% | |
| Form 10-Q ACTUATE THERAPEUTICS, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +2.08% | -9.03% | |
| Form S-8 ACTUATE THERAPEUTICS, | SEC filing · Form S-8 | SEC EDGAR | +2.08% | -9.03% | |
| Actuate Therapeutics Announces FDA Clearance of IND for Oral Elraglusib and Strategic Initiatives to Advance the Elraglusib Development Program | Press release | GlobeNewswire | +1.41% | -9.02% | |
| Form 8-K ACTUATE THERAPEUTICS, For: May 11 | SEC filing · Form 8-K | SEC EDGAR | +3.11% | +1.05% | |
| Actuate Therapeutics Announces Key Appointment of Industry Veteran to Board of Directors | Press release | GlobeNewswire | -0.97% | -2.92% | |
| Form 8-K ACTUATE THERAPEUTICS, For: May 01 | SEC filing · Form 8-K | SEC EDGAR | -0.67% | -0.33% | |
| Form DEFA14A ACTUATE THERAPEUTICS, | SEC filing · Form DEFA14A | SEC EDGAR | -2.30% | -0.64% | |
| Actuate Therapeutics Announces Nature Medicine Publication of Clinical Trial Results Showing Doubling of the Rate of Survival with Elraglusib Plus Chemotherapy in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma | Press release | GlobeNewswire | -4.30% | +11.83% | |
| Form ARS ACTUATE THERAPEUTICS, For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -7.18% | -11.79% | |
| Form DEF 14A ACTUATE THERAPEUTICS, For: May 21 | SEC filing · Form DEF | SEC EDGAR | -4.61% | -2.30% | |
| Form DEFA14A ACTUATE THERAPEUTICS, | SEC filing · Form DEFA14A | SEC EDGAR | -4.61% | -2.30% | |
| Form 10-K ACTUATE THERAPEUTICS, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +0.00% | -4.44% | |
| Actuate Therapeutics: Poised for Potential $200M+ Pediatric Priority Review Vouchers and Transformative Combinations in RAS-Driven Cancers | Press release | ACCESS Newswire | +0.00% | -9.43% | |
| Actuate Therapeutics Launches Strategic Research Initiative to Combine Elraglusib with RAS Inhibitors | Press release | GlobeNewswire | +7.57% | +1.90% | |
| Actuate Therapeutics to Present at The Citizens Life Sciences Conference | Press release | GlobeNewswire | +2.23% | +5.26% | |
| Actuate Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference | Press release | GlobeNewswire | +1.57% | +8.90% | |
| Actuate Therapeutics Announces Plans to Expand Clinical Pipeline, Advancing Elraglusib Tablet into a Phase 1/2 Clinical Program in Refractory Cancers | Press release | GlobeNewswire | +0.00% | +6.16% | |
| Actuate Therapeutics Reports Positive Follow-Up Data from its Randomized Controlled Phase 2 Trial Demonstrating Extended Long-Term Overall Survival Benefit with Elraglusib Plus Chemotherapy for Metastatic Pancreatic Cancer in Oral Presentation at ASCO GI | Press release | GlobeNewswire | -3.74% | -6.50% | |
| Form 8-K ACTUATE THERAPEUTICS, For: Jan 12 | SEC filing · Form 8-K | SEC EDGAR | +0.06% | -3.83% | |
| Actuate Therapeutics Announces Positive Patient Outcomes from Phase 1 Trial in Difficult-to-Treat Refractory Pediatric Cancers | Press release | GlobeNewswire | +1.01% | +0.45% | |
| Actuate Therapeutics Phase 2 Metastatic Pancreatic Cancer Data Selected for Oral and Poster Presentation at ASCO GI 2026 | Press release | GlobeNewswire | — | +1.89% | |
| Actuate Therapeutics Announces Publication of Positive Phase II Clinical Data for Elraglusib Combined with Platinum Chemotherapy and Sequential Immunotherapy in Recurrent, Metastatic Salivary Gland Carcinoma | Press release | GlobeNewswire | -2.08% | -10.91% | |
| Form 8-K ACTUATE THERAPEUTICS, For: Nov 28 | SEC filing · Form 8-K | SEC EDGAR | -3.60% | -4.40% | |
| Form 8-K ACTUATE THERAPEUTICS, For: Nov 21 | SEC filing · Form 8-K | SEC EDGAR | -4.23% | -1.88% | |
| Actuate Therapeutics Provides FDA with Updated Clinical Data Package to Support Planned Regulatory Interactions with FDA and EMA Over the Coming Months | Press release | GlobeNewswire | +4.73% | +5.82% | |
| Actuate Therapeutics Announces Closing of $17.25 Million Public Offering of Common Stock, Including Full Exercise of Over-Allotment Option | Press release | GlobeNewswire | -1.22% | -4.44% | |
| Actuate Therapeutics Announces Pricing of $15.0 Million Public Offering of Common Stock | Press release | GlobeNewswire | -0.31% | +7.50% | |
| Form 8-K ACTUATE THERAPEUTICS, For: Sep 10 | SEC filing · Form 8-K | SEC EDGAR | -1.15% | -0.29% | |
| Actuate Therapeutics Announces Proposed Public Offering of Common Stock | Press release | GlobeNewswire | -0.31% | +7.50% | |
| Form EFFECT ACTUATE THERAPEUTICS, | SEC filing · Form EFFECT | SEC EDGAR | +1.13% | +6.51% | |
| Form S-3 ACTUATE THERAPEUTICS, | SEC filing · Form S-3 | SEC EDGAR | +2.86% | -1.60% | |
| Actuate Therapeutics Advances a New Era in Oncology with Potential Universal Backbone Therapy | Press release | ACCESS Newswire | +0.48% | -4.32% | |
| Form 10-Q ACTUATE THERAPEUTICS, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -1.00% | +1.75% | |
| Actuate Therapeutics To Collaborate with Incyte Corporation and the University of Pittsburgh on Clinical Trial of Elraglusib in Combination with Retifanlimab and mFOLFIRINOX in Patients with Advanced Pancreatic Cancer | Press release | GlobeNewswire | +7.39% | +6.80% | |
| Form EFFECT ACTUATE THERAPEUTICS, | SEC filing · Form EFFECT | SEC EDGAR | +0.00% | +3.83% | |
| Form S-1 ACTUATE THERAPEUTICS, | SEC filing · Form S-1 | SEC EDGAR | -1.29% | -4.59% | |
| Actuate Therapeutics Advances Clinical Program in Ewing Sarcoma After Positive Phase 1 Trial Demonstrates Complete and Partial Responses in Difficult-to-Treat Pediatric Sarcomas | Press release | GlobeNewswire | -11.83% | -13.89% | |
| Form D ACTUATE THERAPEUTICS, | SEC filing · Form D | SEC EDGAR | +3.46% | +2.80% | |
| Form 8-K ACTUATE THERAPEUTICS, For: Jun 25 | SEC filing · Form 8-K | SEC EDGAR | -2.08% | -13.65% | |
| Actuate Therapeutics Highlights Significant and Sustained Survival Benefit in Key Metastatic Pancreatic Cancer Patient Populations in Phase 2 Elraglusib Trial | Press release | GlobeNewswire | -2.61% | -7.41% | |
| Actuate Therapeutics Reports Positive Biomarker and Machine Learning Data from Phase 2 Elraglusib Trial in First-Line Treatment of Metastatic Pancreatic Cancer at ASCO | Press release | GlobeNewswire | +1.12% | -7.09% | |
| Actuate Therapeutics Announces Inclusion in the Russell 3000® and Russell 2000® Indexes | Press release | GlobeNewswire | +0.00% | -4.34% | |
| Form 8-K ACTUATE THERAPEUTICS, For: May 31 | SEC filing · Form 8-K | SEC EDGAR | — | -0.66% | |
| Actuate Therapeutics Shares Highlights from KOL Event on Positive Topline Elraglusib Phase 2 Data in First-Line Treatment of Metastatic Pancreatic Cancer | Press release | GlobeNewswire | -7.09% | -9.49% | |
| Form 8-K ACTUATE THERAPEUTICS, For: May 31 | SEC filing · Form 8-K | SEC EDGAR | -7.09% | -9.49% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the ACTU section they belong to.
Where else ACTU is measured.
ACTU earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Actuate Therapeutics, Inc. - Common stock's median reaction calculated?
Every labeled ACTU news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 170 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 27% of ACTU's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-08-31.
Does ACTU's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.